[Photo: Celltrion via Newsis]
South Korean pharmaceutical giant Celltrion said Monday a clinical trial has demonstrated the safety of its inhaled COVID-19 treatment candidate.
Celltrion said a total of 24 healthy volunteers in Australia were enrolled in a Phase 1 clinical trial of the nebulized antibody treatment conducted by Inhalon Biopharma and there were no severe adverse reactions or related discontinuation of medication.
The company added that it plans to accelerate the development of a cocktail therapy using the inhaled candidate with CT-P63, another candidate antibody for treating COVID-19.
CT-P63, a monoclonal antibody that targets the SARS-CoV-2 spike receptor binding domain as a treatment for infection, has shown a neutralizing ability against earlier variants -- alpha, beta, gamma and delta.
It is different from Celltrion's Regkirona, a monoclonal antibody with activity against COVID-19.
Celltrion said it completed the submission of phase three clinical trial plans for the inhaled cocktail antibody therapy in Bosnia, Serbia and North Macedonia.
Please send comments to firstname.lastname@example.org / copyright © tbs. Unauthorized redistribution prohibited.